EXHIBIT 10.1
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks
denote omissions.
MASTER SERVICES
AGREEMENT
This Master Services Agreement
(“Agreement”) is made between Icagen, Inc., which has a
place of business at 4222 Emperor Blvd., Suite 350, Durham, NC
27703 (hereinafter “Sponsor”), and Quintiles, Inc. a
North Carolina corporation having its principal place of business
at 5927 S. Miami Blvd., Morrisville, NC 27560 (hereinafter
“Quintiles”). When signed by both parties, this
Agreement will set forth the terms and conditions under which
Quintiles agrees to provide certain services to Sponsor as set
forth herein.
Recitals:
A. Sponsor is in the business of
developing, manufacturing and/or distributing pharmaceutical
products, medical devices and/or biotechnology products. Quintiles
is in the business of providing clinical trial services, research,
and other services for the pharmaceutical, medical device and
biotechnology industries and has made significant, up-front
investments in technologies related to those industries, building
on important inventions and web-based technologies.
B. Sponsor and Quintiles desire to
enter into this Agreement to provide the terms and conditions upon
which Sponsor may engage Quintiles from time-to-time to provide
services for individual studies or projects by executing individual
Work Orders (as defined below) specifying the details of the
services and the related terms and conditions.
Agreement:
|
1.0
|
Scope of the
Agreement; Work Orders; Nature of Services.
|
|
|
(a)
|
Scope of
Agreement . As a
“master” form of contract, this Agreement allows the
parties to contract for multiple projects through the issuance of
multiple Work Orders (as discussed in Section 1(b) below),
without having to re-negotiate the basic terms and conditions
contained herein. This Agreement covers the provision of services
by Quintiles and Quintiles’ corporate affiliates (see
Section 18) and, accordingly, this Agreement represents a
vehicle by which Sponsor can efficiently contract with Quintiles
and its corporate affiliates for a broad range of
services.
|
|
|
(b)
|
Work Orders
. The specific details of each
project under this Agreement (each “Project”) shall be
separately negotiated and specified in writing on terms and in a
form acceptable to the parties (each such writing, a “Work
Order”). A sample Work Order is attached hereto as Exhibit A.
Each Work Order will include, as appropriate, the scope of work,
time line, and budget and payment schedule. Each Work Order shall
be subject to all of the terms and conditions of this Agreement, in
addition to the specific details set forth in the Work Order. To
the extent any terms or provisions of a Work Order conflict with
the terms and provisions of this Agreement, the terms and
provisions of this Agreement shall control, except to the extent
that the applicable Work Order expressly and specifically states
an
|
|
|
|
|
|
|
|
00068901
|
|
1
|
|
CONFIDENTIAL
|
|
Icagen, Inc.
05.14.08
|
|
|
|
June 24, 2008
|
|
|
intent to supersede the Agreement on
a specific matter. All Work Orders and other exhibits hereto shall
be deemed to be incorporated herein by reference.
|
|
|
(c)
|
Nature of
Services . The services
covered by this Agreement may include strategic planning, expert
consultation, clinical trial services, statistical programming and
analysis, data processing, data management, regulatory, clerical,
project management, central laboratory services, clinical
pharmacology services, electrocardiogram (ECG) services, medical
device services, and other research and development services
requested by Sponsor and agreed to by Quintiles as set forth in the
relevant Work Order (collectively, the “Services”).
Quintiles and Sponsor, where appropriate, shall cooperate in the
completion of a Transfer of Obligations Form in conjunction with
the relevant Work Order. Any responsibilities not specifically
transferred in the Transfer of Obligations Form shall remain the
regulatory responsibility of Sponsor. The Transfer of Obligations
Form will be filed with the Food and Drug Administration
(“FDA”) by Sponsor where appropriate, or as required by
law or regulation.
|
|
2.0
|
Payment of
Fees and Expenses. Sponsor will pay Quintiles for fees, expenses
and pass- through costs in accordance with the budget and payment
schedule contained in each Work Order. Based on the estimated cash
flow of the Project, Sponsor agrees that a prepayment may be needed
for Quintiles to maintain cash neutrality over the term of the
Project taking into account the payment terms agreed to between the
parties. Unless otherwise agreed in a particular Work Order, the
following shall apply: (a) Quintiles will invoice Sponsor in
accordance with the budget and payment schedule for its fees, and
monthly for its expenses and pass-through costs incurred in
performing the Services; and, (b) with the exception of any
prepayment or advances and investigator invoices, which are due and
payable upon receipt, all other invoice payments shall be made to
Quintiles within thirty (30) days of receipt. In the event
that taxes or duties, of whatever nature, are required to be made
or withheld on payments made pursuant to this Agreement or an
applicable Work Order by any state, federal, provincial or foreign
government, including, but not limited to, Value Added Tax, Sponsor
shall promptly pay said taxes and duties to the appropriate taxing
authority without any deduction to any amount owed to Quintiles.
Sponsor shall secure and deliver to Quintiles any official receipt
for any such taxes paid. Alternatively, Quintiles may invoice
Sponsor for the taxes, without a mark-up, as a pass-through
expense, collect the taxes from Sponsor, and pay the taxes due on
the Services. For the avoidance of doubt, the requirements of this
provision shall not apply to any employment-related taxes, duties,
or withholding and shall only apply to taxes applicable to the
Services. Expenses and pass-through costs will be supported by a
summary sheet. For Projects over multiple calendar years, the
budget will include an annualization percentage. If any portion of
an invoice is disputed, then Sponsor shall pay the undisputed
amounts as set forth in the preceding sentence and the parties
shall use good faith efforts to reconcile the disputed amount as
soon as practicable. Sponsor shall pay Quintiles interest in an
amount equal to one percent (1%) per month (or the maximum
lesser amount permitted by law) of all undisputed amounts owing
hereunder and not paid within thirty (30) days of the date of
the invoice.
|
|
|
|
|
|
|
|
00068901
|
|
2
|
|
CONFIDENTIAL
|
|
Icagen, Inc.
05.14.08
|
|
|
|
June 24, 2008
|
|
3.0
|
Term. This Agreement shall commence on the date it has
been signed by all parties and shall continue for a period of five
(5) years from the date of execution, or until terminated by
either party in accordance with Section 17 below. The
Agreement will automatically renew each year thereafter for a
period of one year, unless either party notifies the other party in
writing at least 30 days prior to the renewal date that it does not
want to renew the Agreement.
|
|
4.0
|
Change
Orders. Any change in the
details of a Work Order or the assumptions upon which the Work
Order is based (including, but not limited to, changes in an agreed
starting date for a Project or suspension of the Project by
Sponsor) may require changes in the budget and/or time lines, and
shall require a written amendment to the Work Order (a
“Change Order”). Each Change Order shall detail the
requested changes to the applicable task, responsibility, duty,
budget, time line or other matter. The Change Order will become
effective upon the execution of the Change Order by both parties,
and Quintiles will be given a reasonable period of time within
which to implement the changes. Both parties agree to act in good
faith and promptly when considering a Change Order requested by the
other party. Without limiting the foregoing, Sponsor agrees that it
will not unreasonably withhold approval of a Change Order, even if
it involves a fixed price contract, if the proposed changes in
budgets or time lines result from, among other appropriate reasons,
forces outside the reasonable control of Quintiles or changes in
the assumptions upon which the initial budget or time lines were
based, including, but not limited to, the assumptions set forth in
the budget or timelines. Quintiles reserves the right to postpone
effecting material changes in the Project’s scope until such
time as the parties agree to and execute the corresponding Change
Order. For any Change Order that affects the scope of the
regulatory obligations that have been transferred to Quintiles,
Quintiles and Sponsor shall execute a corresponding amendment to
the Transfer of Obligations Form. Sponsor shall file such amendment
where appropriate, or as required by law or regulation.
|
|
5.0
|
Confidentiality. It is understood that during the course of this
Agreement, Quintiles and its employees may be exposed to data and
information that are confidential and proprietary to Sponsor. All
such data and information (hereinafter “Sponsor Confidential
Information”) written or verbal, tangible or intangible, made
available, disclosed, or otherwise made known to Quintiles and its
employees as a result of Services under this Agreement shall be
considered confidential and shall be considered the sole property
of Sponsor. All information regarding Quintiles’ operations,
methods, and pricing and all Quintiles’ Property (as defined
in Section 6.0 below), disclosed by Quintiles to Sponsor in
connection with this Agreement is proprietary, confidential
information belonging to Quintiles (the “Quintiles
Confidential Information”, and together with the Sponsor
Confidential Information, the “Confidential
Information”). The Confidential Information shall be used by
the receiving party and its employees only for purposes of
performing the receiving party’s obligations hereunder. Each
party agrees that it will not reveal, publish or otherwise disclose
the Confidential Information of the other party to any third party
without the prior written consent of the disclosing party. Each
party agrees that it will not disclose the terms of this Agreement
or any Work Order to any third party without the written consent of
the other party, which shall not unreasonably be
withheld.
|
|
|
|
|
|
|
|
00068901
|
|
3
|
|
CONFIDENTIAL
|
|
Icagen, Inc.
05.14.08
|
|
|
|
June 24, 2008
|
These obligations of
confidentiality, nondisclosure, and nonuse shall remain in effect
for a period of ten (10) years after the completion or
termination of the applicable Work Order.
The foregoing obligations shall not
apply to Confidential Information to the extent that it: (a) is or
becomes generally available to the public other than as a result of
a disclosure by the receiving party; (b) becomes available to
the receiving party on a non-confidential basis from a source which
is not prohibited from disclosing such information; (c) was
developed independently of any disclosure by the disclosing party
or was known to the receiving party prior to its receipt from the
disclosing party, as shown by contemporaneous written evidence; or,
(d) is required by law or regulation to be
disclosed.
|
6.0
|
Ownership
and Inventions. All data
and information generated or derived by Quintiles as the result of
services performed by Quintiles under this Agreement shall be and
remain the exclusive property of Sponsor. Any inventions that may
evolve from the data and information described above or as the
result of services performed by Quintiles under this Agreement
shall belong to Sponsor and Quintiles agrees to assign its rights
in all such inventions and/or related patents to Sponsor.
Notwithstanding the foregoing, Sponsor acknowledges that Quintiles
possesses certain inventions, processes, know-how, trade secrets,
improvements, other intellectual properties and other assets,
including but not limited to analytical methods, procedures and
techniques, procedure manuals, personnel data, financial
information, computer technical expertise and software, which have
been independently developed by Quintiles and which relate to its
business or operations (collectively “Quintiles’
Property”). Sponsor and Quintiles agree that any
Quintiles’ Property or improvements thereto which are used,
improved, modified or developed by Quintiles under or during the
term of this Agreement are the sole and exclusive property of
Quintiles.
|
|
7.0
|
Records and
Materials. At the
completion of the Services by Quintiles, all materials, information
and all other data owned by Sponsor, regardless of the method of
storage or retrieval, shall be delivered to Sponsor in such form as
is then currently in the possession of Quintiles, subject to the
payment obligations set forth in Section 2 herein.
Alternatively, at Sponsor’s written request, such materials
and data may be retained by Quintiles for Sponsor for an
agreed-upon time period, or disposed of pursuant to the written
directions of Sponsor. Sponsor shall pay the costs associated with
any of the above options and shall pay a to-be-determined fee for
storage by Quintiles of records and materials after completion or
termination of the Services. Quintiles, however, reserves the right
to retain, at its own cost and subject to the confidentiality
provisions herein, copies of all materials that may be needed to
satisfy regulatory requirements or to resolve disputes regarding
the Services. Nothing in this Agreement shall be construed to
transfer from Sponsor to Quintiles any FDA or regulatory
record-keeping requirements unless such transfer is specifically
provided for in the applicable Transfer of Obligations
Form.
|
|
|
|
|
|
|
|
00068901
|
|
4
|
|
CONFIDENTIAL
|
|
Icagen, Inc.
05.14.08
|
|
|
|
June 24, 2008
|
|
8.0
|
Independent
Contractor Relationship. For the purposes of this Agreement, the parties
hereto are independent contractors and nothing contained in this
Agreement shall be construed to place them in the relationship of
partners, principal and agent, employer/employee or joint
venturers. Neither party shall have the power or right to bind or
obligate the other party, and neither party shall hold itself out
as having such authority. If, however, Sponsor desires to conduct
clinical trials in one or more countries that require a local
representative, and Sponsor requests that Quintiles or its
affiliates serve as its agent for that purpose, then Quintiles may
serve as Sponsor’s agent for the purpose of fulfilling local
sponsor or representative duties. Sponsor shall pay Quintiles for
such local representative services at Quintiles’ standard
daily rates, unless otherwise specified in the attached
Budget.
|
Certain countries require that the
local representative must indemnify sites for harm caused by the
Study Drug or otherwise assume primary responsibility for harm
caused by the Study Drug. Those countries are currently Singapore,
Australia, Indonesia, Korea, Taiwan, China (depending on local
regulatory requirements) and Mexico (if IMSS sites are used). If
Sponsor requests that Quintiles serve as its local representative
in those countries, the parties must negotiate and enter into a
Local Representative Agreement, either as part of the applicable
Work Order or as a stand alone agreement. In addition, if Sponsor
is not based in the European Union (“EU”) and services
will be performed in the EU, Sponsor may request that Quintiles
serve as its Legal Representative in the EU, and, if Quintiles
agrees, the parties will negotiate and enter into a separate
agreement specifying the terms of such legal
representation.
|
9.0
|
a)
Regulatory Compliance. Quintiles agrees that its Services will be
conducted in compliance with all applicable laws, rules and
regulations, including but not limited to the Federal Food, Drug,
and Cosmetic Act and the regulations promulgated pursuant thereto,
and with the standard of care customary in the contract research
organization industry. Regarding the FDA’s electronic records
and signatures regulation, 21 CFR Part 11 (“Part 11”),
Quintiles has a compliance plan in place as to its applicable
database applications and electronic records systems and it is
working diligently to implement its plan. Quintiles, however, is
not responsible for the compliance or non-compliance of
applications or systems used by third parties (including, but not
limited to, investigative sites or third party laboratories), or
any Part 11 audits or assessments thereof, unless such applications
or systems are owned by Quintiles. Quintiles’ standard
operating procedures will be used in performance of the Services,
unless otherwise specifically stated in the Scope of Work.
Quintiles certifies that it has not been debarred under the Generic
Drug Enforcement Act and that it will not knowingly employ any
person or entity that has been so debarred to perform any Services
under this Agreement. Sponsor represents and certifies that it will
not require Quintiles to perform any assignments or tasks in a
manner that would violate any applicable law or regulation. Sponsor
further represents that it will cooperate with Quintiles in taking
any actions that Quintiles reasonably believes are necessary to
comply with the regulatory obligations that have been transferred
to Quintiles.
|
|
|
|
|
|
|
|
00068901
|
|
5
|
|
CONFIDENTIAL
|
|
Icagen, Inc.
05.14.08
|
|
|
|
June 24, 2008
|
b) Inspections and
Audits. Each party
acknowledges that the other party may respond independently to any
regulatory correspondence or inquiry in which such party or its
affiliates is named. Each party, however, shall notify the other
party promptly of any FDA or other governmental or regulatory
inspection or inquiry concerning any study or Project of Sponsor in
which Quintiles is providing Services. During any such inspection
or inquiry, the parties agree to make reasonable efforts to
disclose only the information required to be disclosed. During the
term of this Agreement, Quintiles will permit Sponsor’s
representatives (unless such representatives are competitors of
Quintiles) to examine or audit the work performed hereunder and the
facilities at which the work is conducted upon reasona
|